Seidu, S., Kunutsor, S. K., & Khunti, K. (2019). Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis. *Scandinavian Cardiovascular Journal*, 53(6), 286-295.
<https://doi.org/10.1080/14017431.2019.1655166>

Peer reviewed version

Link to published version (if available):
[10.1080/14017431.2019.1655166](https://doi.org/10.1080/14017431.2019.1655166)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Taylor and Francis at <https://www.tandfonline.com/doi/full/10.1080/14017431.2019.1655166> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis

Samuel Seidu^{1,2}, Setor Kunutsor³, Melanie J Davies^{1,2} Kamlesh Khunti^{1,2}

¹Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4WP, UK

²Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4WP, UK.

³National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK

Translational Health Sciences, Bristol Medical School, Musculoskeletal Research Unit, University of Bristol, Learning & Research Building (Level 1), Southmead Hospital, Bristol, BS10 5NB, UK

Correspondence to: Samuel Seidu, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4WP, UK. Email:

Abstract

Background: Circulating osteocalcin (OC), a marker which is central in bone mineralization, may be involved in the atherosclerotic process and influence the risk of developing cardiovascular disease (CVD).

Aims: We conducted a systematic review and meta-analysis of published observational evidence, to assess and quantify the associations of circulating OC (total, undercarboxylated, and carboxylated OC) with cardiovascular outcomes (clinical CVD endpoints and intermediate cardiovascular phenotypes).

Methods: Relevant studies were identified in a literature search of MEDLINE, EMBASE, and reference lists of relevant studies to March 2019. Mean differences and risk ratios with 95% CIs were aggregated using random-effects models.

Results: Thirty-three observational studies (prospective and retrospective cohort, case-control, and cross-sectional) with data on 21,021 unique participants were eligible. The pooled risk ratio in a comparison of extreme fourths of total OC levels was 0.98 (95% CI 0.89, 1.08) for composite CVD. Circulating total OC levels were significantly lower in patients with cardiovascular conditions compared with those without these conditions -2.58 ng/ml (95% CI -3.85, -1.32; $p < 0.001$). Prospective and cross-sectional data showed significant inverse associations between total OC and traits such as aortic or coronary calcification, coronary atherosclerosis or calcification, carotid intima-media thickness, and plaque score. There was limited data on carboxylated and undercarboxylated OC, with no evidence of associations.

Conclusion: Observational evidence generally supports inverse associations of circulating total OC with risk of atherosclerotic outcomes and CVD endpoints; however, the data were mostly based on cross-sectional evaluations. Large-scale prospective data are needed.

Keywords: osteocalcin; cardiovascular disease; coronary heart disease; atherosclerosis; carotid intima-media thickness; meta-analysis

Introduction

Cardiovascular disease (CVD) is still the leading cause of global mortality.(1) By 2030, an estimated 23.6 million people will die from CVD.(2) Major risk factors for CVD include a history of diabetes, high blood pressure, raised blood lipids, as well as smoking status.(3) Though these established risk factors explain a large proportion of the risk of CVD, its pathogenesis is still not fully established as it appears other additional factors may be involved. Osteocalcin (OC), a bone matrix protein mainly expressed by osteoblasts(4) and used as a biochemical indicator of bone formation,(5) has been proposed as a potential biomarker of CVD risk. Osteocalcin is secreted by osteoblasts in a fully carboxylated form, which is then decarboxylated to a more active biological form (4, 6, 7).

Circulating blood levels of total OC comprises both carboxylated and undercarboxylated OC. Serum OC has been investigated as a hormone which plays a role in regulating glucose metabolism and fat mass; it promotes insulin sensitivity and secretion by pancreatic β -cells, as well as increases proliferation of the β -cells and stimulates energy metabolism.(6) Reduced circulating levels of OC have been consistently linked with high blood glucose levels, insulin resistance, and type 2 diabetes.(6, 8-10). Indeed, it has been discussed that OC may hold potential for the prevention, delay and treatment of obesity and metabolic disorders such as diabetes.(8) Emerging evidence also suggests circulating OC may be involved in CVD development, but the data are sparse and conflicting. A number of studies have shown reduced levels of circulating OC to be associated with adverse cardiovascular outcomes such as arterial calcification, carotid atherosclerosis, increased carotid intima-media thickness (CIMT), and CVD;(11-13) whereas others have not demonstrated any relationships.(14, 15). In this context, we performed a systematic review and meta-analysis of all available published observational evidence to clarify and quantify the extent of potential associations of circulating OC (total, uncarboxylated, and carboxylated OC) with (i) clinical CVD outcomes as well as all-cause mortality; and (ii) intermediate cardiovascular traits. We also sought to identify gaps in the existing evidence.

Methods

Data sources and search strategy

This review was conducted using a predefined protocol and in accordance with PRISMA and MOOSE guidelines (16, 17) (**Appendix 1-2**). We searched MEDLINE and EMBASE up to 22 March 2019. The computer-based searches combined terms related to the exposure (e.g., “osteocalcin”) and outcomes (e.g., “cardiovascular disease”, “coronary heart disease”, “atherosclerosis”, “carotid intima-media thickness”, “mortality”) in humans, without any language restriction. Reference lists of selected studies and relevant reviews on the topic were manually scanned for additional publications missed by the original search. Full details on the search strategy are presented in **Appendix 3**.

Eligibility criteria

We systematically searched for observational cohort, case-control, or cross-sectional population-based studies that had reported on associations of circulating levels of OC (total OC, undercarboxylated OC, and carboxylated OC) with (i) CVD-related outcomes [composite CVD, coronary heart disease (CHD), stroke, congestive heart failure (CHF), or all-cause mortality]; and (ii) intermediate cardiovascular traits [carotid atherosclerosis, aortic atherosclerosis, coronary artery calcification (CAC), carotid intima-media thickness (CIMT), abdominal aortic calcification (AAC)].

Data extraction and quality assessment

The titles and abstracts of all articles identified by the broad literature search were assessed independently by two reviewers (SKK and SS). Studies that did not meet inclusion criteria were discarded. Full text of selected articles were retrieved and assessed to determine if they met the inclusion criteria. Those studies which met the inclusion criteria were included in the review and data was extracted independently by two reviewers (SKK and SS) using a standard data extraction form. The quality of the studies was assessed independently by both reviewers

When available, data were extracted on: publication date; study design; geographical location; population source; year of baseline survey; sample population; mean/median age at baseline; duration of follow-up (for cohort studies); type of OC; mean/median levels of OC; type of outcome; and reported risk estimates. In the case of multiple publications involving the same study, data were extracted from the most up-to-date study or study with the most comprehensive information was abstracted. We also corresponded with study investigators to provide missing information where relevant. Any discrepancies regarding eligibility of an article were discussed, and consensus reached with a third reviewer (K.K.). For cohort and case-control studies, study quality was assessed based on the nine-star Newcastle–Ottawa Scale (NOS) (18) using three pre-defined domains namely: selection of participants (population representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of interest. The NOS assigns a maximum of four points for selection, two points for comparability, and three points for outcome. Nine points on the NOS reflects the highest study quality. For cross-sectional studies, quality was evaluated using the NOS modified for cross-sectional studies (**Appendix 4**(10)). A score of 8 reflected the highest study quality.

Statistical analysis

Mean differences for continuous outcomes and risk ratios for categorical outcomes were used as summary measures across studies. A narrative synthesis was performed for studies that could not be pooled. For data reported as medians, standard errors, ranges, and 95% confidence intervals (CIs), means and standard deviations were estimated using methods as described by Hozo and colleagues (19). To enable a consistent approach to the meta-analysis, enhance comparability and interpretation of the findings, units of measurements were converted where appropriate and reported study-specific risk ratios (per-unit or standard deviation change, quintiles, or other groupings) were also transformed to involve comparisons between the top quartile and bottom quartile of each study population's baseline distribution of OC levels, using standard statistical methods.(20, 21) described previously.(22-24) To account for the effect of between-study heterogeneity anticipated, we used the

inverse variance weighted method to combine summary measures using random-effects models.(25) We evaluated for publication bias using funnel plots and Egger's regression symmetry tests (26). All tests were two-tailed and p-values of 0.05 or less were considered significant. STATA release 14 (Stata Corp, College Station, Texas, USA) was used for all statistical analyses.

Results

Study identification and selection

165 potentially relevant citations were identified. 40 articles were selected for full text evaluation after an initial screen based on titles and abstracts. After detailed assessments, 8 articles were excluded because (i) the outcomes were not relevant to review (n=5); (ii) the exposure was not relevant (n=2); and (ii) one article used the same population sample as another study included in the review. The remaining 32 articles based on 33 unique observational studies met all inclusion criteria and were included in the review (**Figure 1; Appendix 5**).

Study characteristics and study quality

Table 1 shows a summary of the key characteristics of the included. 21,021 unique participants were included in this review. However, not all studies provided relevant data that could be included in the quantitative synthesis. The majority of studies (n=19) were conducted in Asia (China, Japan, and South Korea); with 10 in Europe (Austria, France, Germany, Italy, The Netherlands, and Spain); 2 in the Pacific (Australia); and 2 in North America (USA). The mean/median baseline age of participants ranged from 49 to 77 years. The majority of studies (n=20) were cross-sectional in design; 9 prospective cohorts; 2 case-controls; 1 retrospective cohort and 1 prospective case-control. The average follow-up for cohort studies ranged from 0.5 to 10.0 years. For studies that provided relevant data on their recruitment processes, majority of studies (n=22) reported recruiting patients from healthcare settings, with 7 studies reporting recruitment from a population register. There was considerable variability in study populations which included healthy and community-dwelling

participants, post-menopausal women, and patients with pre-existing conditions such as type 2 diabetes, chronic kidney disease, essential hypertension and those at high cardiovascular risk. Among cohort, case-control, and cross-sectional studies, quality score ranged from 3 to 8.

Association of circulating osteocalcin with cardiovascular outcomes

Cohort analysis The pooled risk ratio of 5 cohort studies (3481 participants and 686 events) for composite CVD risk comparing individuals in the top versus bottom fourths of circulating total OC levels, adjusted for several established cardiovascular risk factors was 0.98 (95% CI 0.89, 1.08; $p=0.669$) (**Figure 2**). The prospective corresponding risk ratios for CHD and stroke based on results of a single study were 1.06 (95% CI 0.38, 2.93) and 0.65 (95% CI 0.29, 1.46) respectively.

In pooled analysis of 2 prospective studies (1,760 participants and 378 events), the multivariate-adjusted risk ratio for all-cause mortality was 0.33 (95% CI 0.03, 3.51; $p=0.355$) comparing individuals in the top versus bottom fourths of circulating total OC levels. Four studies could not be included in the meta-analysis because of differences in the exposure categories. In analysis adjusted for several conventional risk factors, Yeap and colleagues reported a U-shaped relationship of circulating total OC with CVD mortality and all-cause mortality in men – the risk being increased at both ends of the distribution of OC levels.(27). In a follow-up of the same study that evaluated CHD and stroke outcomes, total OC was not associated with MI or stroke events.(15) In the Ludwigshafen Risk and Cardiovascular Health (LURIC) prospective cohort study,(28) findings reported in men showed a U-shaped association of total OC with fatal CVD and all-cause mortality - with increased risk at both ends of the distribution of OC levels. In a prospective case-control study of 102 MI patients and 200 control subjects, total OC was demonstrated to be associated with premature MI at one-year follow-up.(29)

In the single prospective cohort study that evaluated the associations between undercarboxylated OC and cardiovascular endpoints, there was no evidence of an association of undercarboxylated OC with CHD or stroke.(15)

Cross-sectional analysis Comparing individuals in the top versus bottom fourths of circulating total OC levels, the multivariate-adjusted risk ratio for CHD in pooled analysis of 3 cross-sectional studies (766 participants and 383 events) was 1.20 (95% CI 0.32, 4.50; $p=0.789$).

Association of serum total osteocalcin with intermediate cardiovascular traits

Cohort analysis The pooled risk ratio for aortic calcification in pooled analysis of 2 prospective cohort studies was 0.87 (95% CI 0.76, 0.99; $p=0.030$) comparing individuals in the top versus bottom fourths of circulating total OC levels. In a prospective cohort study that monitored changes in total OC and plaque score in Japanese patients with type 2 diabetes, changes in circulating total OC was inversely associated with changes in plaque score from baseline in analysis adjusted for atherosclerotic risk factors ($\beta=-0.30$; $p=0.047$).⁽³⁰⁾

Cross-sectional analysis In pooled analysis of 8 studies (3356 participants), the multivariate-adjusted risk ratio for vascular atherosclerosis or calcification when comparing individuals in the top versus bottom fourths of circulating total OC levels was 0.67 (95% CI 0.37, 1.22; $p=0.187$) (**Figure 3**). The risk ratio for vascular atherosclerosis or calcification when comparing individuals in the top versus bottom fourths of circulating undercarboxylated OC levels in pooled analysis of 4 studies (762 participants) was 0.76 (95% CI 0.13, 4.63; $p=0.767$) (**Figure 3**).

Five studies could not be included in the meta-analysis. Kanazawa and colleagues in their assessment of the associations of serum total OC with atherosclerosis parameters in patients with type 2 diabetes, total OC was significantly and inversely correlated with CIMT in men ($r=-0.181$; $p=0.023$), but not in women ($r=0.022$; $p=0.803$).⁽³¹⁾ In a sample of 817 men and postmenopausal women with type 2 diabetes, serum total OC was independently and inversely associated with CIMT ($\beta=-0.181$; $r=-0.187$; $p<0.001$).⁽¹²⁾ Yang and colleagues also demonstrated a significant and inverse association between serum total OC and CIMT ($\beta=-0.117$; $r=-0.107$; $p<0.01$).⁽¹³⁾ Kim and colleagues also reported total OC to be significantly and inversely correlated with aortic calcification as

measured by the aortic calcium score ($r=-0.238$; $p<0.001$).⁽¹¹⁾ An independent and inverse correlation ($\beta=-0.497$; $p=0.003$) was also demonstrated between serum total OC and coronary atherosclerosis index in the study by Bao and colleagues.⁽³²⁾

Circulating osteocalcin levels in patients with cardiovascular outcomes and traits compared with controls

The pooled random-effects mean difference across 9 studies showed significantly lower circulating levels of total OC -2.58 ng/ml (95% CI -3.85 , -1.32 ; $p<0.001$) in patients with cardiovascular conditions compared to subjects without cardiovascular conditions (**Figure 4**). In pooled analysis of 4 studies, there was no significant difference in circulating undercarboxylated OC levels comparing subjects with and without cardiovascular conditions. In a case-control study, circulating carboxylated OC level was significantly lower comparing subjects with and without CAD -0.50 ng/ml (95% CI -0.71 , -0.29 ; $p<0.001$).

Discussion

Summary of findings

Using a systematic and meta-analytical approach, we have summarized all available observational studies that have assessed the associations of circulating levels of OC (total, undercarboxylated, and carboxylated OC) with clinical CVD endpoints and intermediate CVD traits, in an attempt to address the uncertainties in the evidence. In the analysis of hard CVD outcomes, pooled analysis of prospective data showed no evidence of statistically significant associations of total OC with composite CVD, CHD, or stroke endpoints. However, two prospective studies conducted in men demonstrated a U-shaped association of total OC with fatal CVD and all-cause mortality.^(27, 28) Both low and high levels of total OC were associated with an increased risk of these outcomes. In the evaluation of intermediate cardiovascular traits, prospective data showed significant inverse associations between total OC and traits such as aortic calcification and plaque score. Though the

evidence from cross-sectional studies was inconsistent, majority of studies reported inverse, independent, and significant correlations between total OC and outcomes such as CIMT, aortic calcification, and coronary calcification or atherosclerosis. Circulating total OC was significantly lower in patients with cardiovascular conditions compared with those without these conditions. The data was limited for undercarboxylated and carboxylated OC and generally no significant evidence of associations were demonstrated with the outcomes assessed.

Interpretation of findings

The current evidence does not conclusively support a role of circulating OC (particularly total OC) in the pathophysiology of adverse cardiovascular lesions as well as CVD risk. Though some of the findings show that reduced levels of circulating total OC are associated with greater pathological cardiovascular changes, there was evidence to suggest that increased levels of total OC might also be associated with increased risk of these adverse outcomes. Beyond its well-established pro-osteoblastic functions(33), OC has been demonstrated to have endocrine functions.(6) Consistent evidence shows that reduced circulating levels of OC is associated with increased risk of adverse metabolic outcomes such as type 2 diabetes and metabolic syndrome (MetS), which is via its role in influencing insulin secretion, glucose metabolism, insulin sensitivity, fat mass, beta cell proliferation, and energy expenditure.(6, 34, 35) Though the mechanistic evidence has mostly involved the use of animal models, recent epidemiological and genetic studies suggest the multiple aspects of the biology of OC are similar for both humans and rodents. (36, 37) However, the mechanistic evidence linking OC with atherosclerotic CVD is unclear compared with metabolic conditions such as type 2 diabetes; a number of pathways have been proposed. Conditions such as insulin resistance, metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes, which are closely linked to circulating OC, accelerate the progression of atherosclerotic lesions and are strongly linked to the development of atherosclerosis.(12) Osteocalcin may be involved in the calcification process at arterial and valvular sites, leading to reduced elasticity and compliance of the vasculature.(38, 39) Osteocalcin may also

play a direct role in the atherosclerotic process, as osteoclast-like cells have been identified in atherosclerotic lesions.(39) Whether the different forms of OC may play different roles in the pathophysiology of adverse cardiovascular outcomes is not clear, as the evidence has mostly been limited to circulating total OC. However, there is evidence from animal models suggesting that undercarboxylated OC, the more active form of OC, may be of more importance in regulating glucose and energy metabolism(6, 34, 40) and therefore could be implicated in the development of adverse metabolic outcomes. This is not well established as it is not even certain if undercarboxylated OC might be the active form in humans (36).

Implications of findings

The current findings provide further insight on the role of OC beyond its pro-osteoblastic properties as well as its role in glucose and energy metabolism. The clinical use of circulating OC assays has mainly been for monitoring and assessing the effectiveness of antiresorptive therapy in patients with bone conditions characterised by elevated OC levels such as osteoporosis and Paget's disease.(41) Though some of the findings were inconsistent which impeded meaningful interpretation, the overall results of the quantitative synthesis of the available data does not underscore a potentially protective role of increased circulating total OC levels on the risk of atherosclerotic lesions and CVD outcomes. The inconsistencies in the findings could be related to the small sample sizes employed by majority of studies, different populations used, different OC assay methods employed, and the fact that circulating OC levels are influenced by ethnicity, gender and menopausal status.(42) There is some suggestion from our results that there may be a more evident association in males. In addition to highlighting the lack of consistent evidence on the cardiovascular effects of OC, this review has also identified several gaps in the literature. Compared with the number of cross-sectional study designs (n=20), only 10 observational cohort studies were identified to have evaluated the associations and these were limited by small sample sizes and populations with pre-existing disease. Furthermore, the majority of studies used assays for total OC, and therefore the role of other forms of OC is far from clear. This

observation could be attributed to the fact that circulating total OC can be conveniently measured in large studies using automated immunoassays (43), while assays for undercarboxylated OC are more cumbersome, labour intensive, or less precise (44). Large-scale prospective studies conducted in general population settings are needed to address the existing research gaps. Thus far, the potential of strategies that raise concentrations of circulating total OC and their value in the prevention or treatment of vascular diseases is not convincing enough. This is a topic which deserves further investigation.

Strengths and limitations

The strengths and limitations of this systematic meta-analysis merit careful consideration. The notable strengths included the comprehensive search strategy which yielded several published studies on the topic. Overall, this review involved over 21,000 participants and evaluated a wide-range of atherosclerotic and CVD outcomes and their relationships with the different forms of circulating OC. We were able to transform reported risk estimates from majority of contributing studies to a consistent comparison (mean differences and top versus bottom fourths) to allow a consistent combination of estimates across studies, therefore obtaining a reliable estimate of the magnitude of the association and enhancing interpretation of the overall findings. We also conducted a detailed quality assessment of eligible studies. Limitations included the inability to fully examine the impact of adjustment for potential confounding factors, because the review was based on variably adjusted data reported in the published literature; heterogeneity could not be explored because of the limited number of studies available for pooling; and some outcomes and risk estimates were inconsistent between studies and therefore could not be pooled.

In conclusion, aggregate observational data do not generally support inverse and independent associations of circulating total OC with risk of atherosclerotic outcomes and CVD endpoints; however, the data were mostly based on cross-sectional evaluations. There are gaps in the existing

literature and large-scale prospective cohort studies are needed to explore the nature and potential magnitude of any association of circulating OC with cardiovascular outcomes.

Acknowledgements

We thank Rebeca Reyes-Garcia, MD, PhD, Bone Metabolic Unit (RETICEF), Endocrinology Division, Hospital Universitario San Cecilio, Av. Dr. Oloriz 16, 18012 Granada, Spain for readily providing data on request.

Funding

S. Seidu, and K. Khunti acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM), the Leicester Clinical Trials Unit and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. S.K. Kunutsor is supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Conflicts of Interest/Disclosures

None

References

1. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol*. 2017;70(1):1-25. doi:10.1016/j.jacc.2017.04.052
2. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2011. http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed January 23, 2018.
3. Wood D. Established and emerging cardiovascular risk factors. *Am Heart J*. 2001;141(2 Suppl):S49-57.
4. Price PA. Gla-containing proteins of bone. *Connective tissue research*. 1989;21(1-4):51-7; discussion 7-60.
5. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. *Osteoporos Int*. 2005;16(12):1506-12. doi:10.1007/s00198-005-1877-5
6. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. *Cell*. 2007;130(3):456-69. doi:10.1016/j.cell.2007.05.047
7. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. *Physiological reviews*. 1989;69(3):990-1047.
8. Villafan-Bernal JR, Sanchez-Enriquez S, Munoz-Valle JF. Molecular modulation of osteocalcin and its relevance in diabetes (Review). *Int J Mol Med*. 2011;28(3):283-93. doi:10.3892/ijmm.2011.706
9. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers. *Osteoporos Int*. 2014;25(6):1697-708. doi:10.1007/s00198-014-2676-7
10. Kunutsor SK, Apekey TA, Laukkanen JA. Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence. *Eur J Epidemiol*. 2015;30(8):599-614. doi:10.1007/s10654-015-0058-x
11. Kim KJ, Kim KM, Park KH, et al. Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin. *Calcif Tissue Int*. 2012;91(6):370-8. doi:10.1007/s00223-012-9642-1
12. Sheng L, Cao W, Cha B, Chen Z, Wang F, Liu J. Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2013;12:22. doi:10.1186/1475-2840-12-22
13. Yang R, Ma X, Dou J, et al. Relationship between serum osteocalcin levels and carotid intima-media thickness in Chinese postmenopausal women. *Menopause*. 2013;20(11):1194-9. doi:10.1097/GME.0b013e31828aa32d

14. Hwang YC, Kang M, Cho IJ, et al. Association between the Circulating Total Osteocalcin Level and the Development of Cardiovascular Disease in Middle-aged Men: A Mean 8.7-year Longitudinal Follow-up Study. *J Atheroscler Thromb*. 2015;22(2):136-43. doi:10.5551/jat.25718
15. Yeap BB, Alfonso H, Chubb SA, et al. Proportion of Undercarboxylated Osteocalcin and Serum P1NP Predict Incidence of Myocardial Infarction in Older Men. *J Clin Endocrinol Metab*. 2015;100(10):3934-42. doi:10.1210/jc.2015-1899
16. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in Epidemiology. *JAMA: The Journal of the American Medical Association*. 2000;283(15):2008-12. doi:10.1001/jama.283.15.2008
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
18. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed 10 March 2015.
19. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC medical research methodology*. 2005;5:13. doi:10.1186/1471-2288-5-13
20. Chêne G, Thompson SG. Methods for Summarizing the Risk Associations of Quantitative Variables in Epidemiologic Studies in a Consistent Form. *American Journal of Epidemiology*. 1996;144(6):610-21.
21. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *American Journal of Epidemiology*. 1992;135(11):1301-9.
22. Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. *Ann Epidemiol*. 2014;24(11):809-16. doi:10.1016/j.annepidem.2014.09.001
23. Kunutsor SK, Apekey TA, Cheung BM. Gamma-glutamyltransferase and risk of hypertension: a systematic review and dose-response meta-analysis of prospective evidence. *J Hypertens*. 2015;33(12):2373-81. doi:10.1097/HJH.0000000000000763
24. Kunutsor SK, Apekey TA, Hemelrijck MV, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: Systematic review and meta-analysis. *Int J Cancer*. 2014. doi:10.1002/ijc.29084
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-88. doi:10.1016/0197-2456(86)90046-2 [pii]
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-34.
27. Yeap BB, Chubb SA, Flicker L, et al. Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study. *Osteoporos Int*. 2012;23(2):599-606. doi:10.1007/s00198-011-1586-1

28. Lerchbaum E, Schwetz V, Pilz S, et al. Association of bone turnover markers with mortality in men referred to coronary angiography. *Osteoporosis International*. 2013;24(4):1321-32. doi:10.1007/s00198-012-2076-9
29. Goliasch G, Blessberger H, Azar D, et al. Markers of bone metabolism in premature myocardial infarction (≤ 40 years of age). *Bone*. 2011;48(3):622-6. doi:10.1016/j.bone.2010.11.005
30. Kanazawa I, Yamaguchi T, Sugimoto T. Relationship between bone biochemical markers versus glucose/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2011;92(3):393-9. doi:10.1016/j.diabres.2011.03.015
31. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2009;94(1):45-9. doi:10.1210/jc.2008-1455
32. Bao Y, Zhou M, Lu Z, et al. Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men. *Clin Endocrinol (Oxf)*. 2011;75(2):196-201. doi:10.1111/j.1365-2265.2011.04065.x
33. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. *Molecular and cellular endocrinology*. 2009;310(1-2):21-9. doi:10.1016/j.mce.2009.04.004
34. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. *Bone*. 2012;50(2):568-75. doi:10.1016/j.bone.2011.04.017
35. Hinoi E, Gao N, Jung DY, et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. *The Journal of cell biology*. 2008;183(7):1235-42. doi:10.1083/jcb.200809113
36. Ducy P. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. *Diabetologia*. 2011;54(6):1291-7. doi:10.1007/s00125-011-2155-z
37. Wei J, Karsenty G. An Overview of the Metabolic Functions of Osteocalcin. *Current osteoporosis reports*. 2015. doi:10.1007/s11914-015-0267-y
38. Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E, calcifications SSjwgov. Vascular calcification: from pathophysiology to biomarkers. *Clin Chim Acta*. 2015;438:401-14. doi:10.1016/j.cca.2014.08.034
39. Yamanouchi D, Takei Y, Komori K. Balanced mineralization in the arterial system: possible role of osteoclastogenesis/osteoblastogenesis in abdominal aortic aneurysm and stenotic disease. *Circulation journal : official journal of the Japanese Circulation Society*. 2012;76(12):2732-7.
40. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. *Trends in endocrinology and metabolism: TEM*. 2008;19(5):161-6. doi:10.1016/j.tem.2008.02.006
41. Magni P, Macchi C, Sirtori CR, Corsi Romanelli MM. Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases. *Clin Chem Lab Med*. 2016;54(10):1579-87. doi:10.1515/cclm-2015-0953

42. Gundberg CM, Looker AC, Nieman SD, Calvo MS. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. *Bone*. 2002;31(6):703-8.
43. Takahashi M, Kushida K, Nagano A, Inoue T. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. *Clin Chim Acta*. 2000;294(1-2):67-76.
44. Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. *J Clin Endocrinol Metab*. 1998;83(9):3258-66. doi:10.1210/jcem.83.9.5126

Figure legends

Figure 1. Selection of studies included in the meta-analysis

Figure 2. Association of circulating total osteocalcin with cardiovascular outcomes and all-cause mortality

CI, confidence interval (bars); OC, osteocalcin

Figure 3. Associations of circulating total and undercarboxylated osteocalcin with intermediate cardiovascular traits

AAC, abdominal aortic calcification; CAC, coronary artery calcification; CI, confidence interval (bars); OC, osteocalcin

Figure 4. Mean differences in circulating osteocalcin levels comparing subjects with cardiovascular conditions and their respective controls

CAC, coronary artery calcification; CAD, coronary artery disease; CHD, coronary heart disease; CHF, congestive heart failure; CI, confidence interval (bars)

Figure 1

Figure 2

Figure 3

Figure 4

Table 1. Characteristics of studies included in review

Lead Author, Publication Date	Name of study or source of participants	Location	Study design	Baseline population	Year of baseline survey	Baseline age range (years)	% male	Follow up (years)	Outcome (s)	Total participants	Covariates adjusted for	Study quality
Jie, 1995	Population-based	Netherlands	Cross-sectional	Post-menopausal	1990	66.6*	0.0	NA	Aortic atheroclerosis	113	NA	4
Schleithoff, 2003	Health setting	Germany	Case-control	CHF patients and controls	2000-2001	66.2-71.5*	100.0	NA	CHF	42	NA	4
Montalcini, 2004	Hospital clinic	Italy	Cross-sectional	Post-menopausal women	NR	45-75	0.0	NA	Carotid atherosclerosis	157	Age, hypertension, hyperlipidemia, type 2 diabetes, obesity, smoker	6
Pennisi, 2004	Hospital setting	Italy	Case-control	Atherosclerotic plaques and/or vascular calcification	2003	62.7*	NR	NA	Carotid/femoral atherosclerosis	66	NA	5
Kanazawa, 2009	Hospital	Japan	Cross-sectional	Type 2 diabetes	NR	50-83 50-84	100.0 0.0	NA	CIMT	179 149	Age, duration of diabetes, BMI, serum creatinine, systolic blood pressure, LDL-C, HDL-C, HbA1C, and Brinkmann index	5
Okura, 2010	NR	Japan	Cross-sectional	Essential hypertension	NR	61.0*	58.0	NA	CAC	92	NR	4
Parker, 2010	SOF	USA	Cross-sectional	Community-dwelling postmenopausal	1986-1988	≥ 65	0.0	NA	AAC	363	Age, body mass index, systolic and diastolic blood pressure, diabetes, hypertension, smoking history, eGFR, CRP, estrogen use, intact parathyroid hormone, bone- specific alkaline phosphatase, and 25-hydroxyvitamin D; hip and spine bone mineral density	6
Zhang, 2010	NR	China	Cross-sectional	Subjects referred for coronary angiography	2005-2007	39-85	64.9	NA	CHD	461	Age, gender, BMI, smoking, alcohol, family history of CHD, LDL-C, HDL-C, TG, type 2 diabetes	6
Bao, 2011	Hospital	China	Cross-sectional	Coronary angiography patients	2008-2009	64.9*	100.0	NA	Coronary atherosclerosis index	181	Age, BMI, fasting insulin, HbA1c, HOMA-IR	6
Goliasch, 2011	Hospital setting	Austria	Case-control	MI patients with controls	2004-2008	≤40	88.7	NA	NA	302	NA	8
Kanazawa, 2011	NR	Japan	Prospective cohort	Type 2 diabetes	NR	64.5*	56.0	0.5	Plaque score	50	Duration of diabetes, Brinkman Index	5
Kim, 2012	SBMS	South Korea	Cross-sectional	Subjects referred for QCT	2007-2010	64.7*	0.0	NA	Aortic atheroclerosis	769	NA	4

Lead Author, Publication Date	Name of study or source of participants	Location	Study design	Baseline population	Year of baseline survey	Baseline age range (years)	% male	Follow up (years)	Outcome (s)	Total participants	Covariates adjusted for	Study quality
Reyes-Garcia, 2012	Endocrinology Unit	Spain	Cross-sectional	Type 2 diabetes	2006-2007	57.8*	55.1	NA	CHD	78	Age, gender, BMI, hypt, smoking, DM duration, aortic calcifications, abnormal IMT, carotid plaques	6
Yeap, 2012	HIMS	Australia	Prospective cohort	Community-dwelling elderly men	2001-2004	77.0*	100.0	5.2	CVD, all-cause mortality	3,542	Age, WHR, conventional CVD risk factors	8
Confavreux, 2013	MINOS	France	Prospective cohort	Elderly men	1995-1996	51-85	100.0	10	AAC, all-cause mortality	774	Age, diabetes, hip to waist ratio, hypertension, smoking status, alcohol intake, serum phosphate, low HDL-cholesterol, AAC score, physical activity, and 25OHD	7
Lerchbaum, 2013	LURIC	Germany	Prospective cohort	Suspected CAD	1997-2000	58.72	100.0	7.7	CVD mortality, all-cause mortality	2,271	Age, BMI, smoking, WHR, CETP, hs-CRP, homocysteine, interleukin-6, HDL cholesterol, LDL cholesterol, triglycerides, prevalent metabolic syndrome	8
Ogawa-Furuya, 2013	Hospital	Japan	Cross-sectional	Type 2 diabetes	2005-2011	64.0*	54.1	NA	AAC	218	Age, BMI, creatinine, LDL-C, radial BMD, smoking, duration of DM, HbA1c, HOMA-IR, BAP, UNTx	6
Sheng, 2013	Shanghai downtown residential areas	China	Cross-sectional	Type 2 diabetes	NR	>50	46.8	NA	Carotid atherosclerosis, CIMT	817	Age, sex, smoking, alcohol, family history of diabetes, WC, HOMA-IR, BMI, WHR, TG, TC, HDL-C, LDL-C, CRP, treatments	6
Yamashita, 2013	Outpatient dialysis center	Japan	Prospective cohort	Maintenance haemodialysis patients	2005	20-85	61.1	5.0	CVD	126	Age, sex, time on dialysis, previous CVD, diabetes, serum Calcium x phosphate product, serum parathyroid hormone levels	7
Yang, 2013	SOS	China	Cross-sectional	Post-menopausal women	NR	41-78	0.0	NA	CIMT	1,319	Age, years since menopause, BMI, WC, SBP, DBP, HOMA-IR, TG, HDL-C, CRP, smoking, treatment, family history of CVD	7
Holvik, 2014	LASA	Netherlands	Prospective cohort	Elderly participants	1995-1996	65-88	48.8	4.1	CVD, ACS	832	Age, BMI, SBP, TG, TC, HDL-C, fructosamine	8
Lerchbaum, 2014	LURIC	Germany	Prospective cohort	Suspected CAD	1997-2000	58.72	0.0	7.7	CVD mortality, all-cause mortality	986	Age, BMI, menopause, prevalent CAD, HRT, vitamin K antagonist use	8
Ma, 2014	Shangai Changfeng study	China	Cross-sectional	Middle-aged and elderly	2009-2012	61.3*	100.0	NA	Carotid atherosclerosis	1,077	Age, FPG, PPG, BMI, WHR, smoking, SBP, DBP, TG, HDL-C, LDL-C, HOMA-IR, HOMA-B	7
Choi, 2015	Hospital	South Korea	Cross-sectional	Asymptomatic patients	2010-2012	53.5	70.4	NA	CAC	162	Age, body mass index, smoking (menopause), hypertension, diabetes, systolic blood pressure, HOMA2-IR, triglycerides, HDL cholesterol and lumbar BMD	6
Hwang, 2015	HPC	Korea	Prospective cohort	Middle-aged men	1997	40-78	100.0	8.7	Composite CVD, CHD, stroke	1,290	Age, BMI, current smoking, LDL-C, diabetes, hypertension, serum creatinine	7

Lead Author, Publication Date	Name of study or source of participants	Location	Study design	Baseline population	Year of baseline survey	Baseline age range (years)	% male	Follow up (years)	Outcome (s)	Total participants	Covariates adjusted for	Study quality
Maser, 2015	Diabetes and Metabolic Research Center	USA	Cross-sectional	Type 2 diabetes	NR	≥ 18	42.0	NA	CAC	50	NA	5
Yeap, 2015	HIMS	Australia	Prospective cohort	Community-based men	2001-2004	70-89	100.0	NA	CHD, stroke	3,384	Education, smoking, BMI, WHR, hypertension, dyslipidemia, diabetes, creatinine, vitamin D, prevalent CVD, cancer	7
Zhang, 2015	Hospital	China	Cross-sectional	Non-dialysis with CKD	NR	50-75	62.9	NA	Carotid atherosclerosis	240	Age, sex, BMI, smoking history, MABP, eGFR, therapeutic medication use, and FBG, TC, TG, LDL-C, HDL-C, and hs-CRP levels	6
Kim, 2016	Hospital	South Korea	Cross-sectional	Patients who underwent CABG	2012--2013	60.7*	100.0	NA	Coronary artery stenosis	122	NA	5
Deng, 2018	Hospital	China	Cross-sectional	Patients who underwent screening for carotid atherosclerosis	2014-2016	40-60	100.0	NA	Carotid atherosclerosis	335	NA	3
Ling, 2018	Hospital	China	Cross-sectional	Post-menopausal women with CAD and controls	2015-2016	66.0*	0.0	NA	CHD, coronary atherosclerosis	227	Age, BMI, smoking, hypertension, diabetes, LDL-C, HDL-C, TG, eGFR, statin use and high-sensitivity CRP	5
Zhang, 2018	Hospital	China	Retrospective cohort	Coronary angiography patients	2008-2009	65.5*	66.4	4.4	CVD	247	Age, BMI, WC, SBP, DBP, FPG, 2hPG, HOMA-IR, TG, HDL-C, LDL-C, CRP, current smoker	6

AAC, abdominal aortic calcification; ACS, aortic calcification score; BMD, bone mineral density; BMI, body mass index; CABG, coronary artery bypass graft; CAC, coronary artery calcification; CAD, coronary artery disease; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; CIMT, carotid artery intima-media thickness; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate, FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HIMS, Health In Men Study; HOMA-B, homeostasis model assessment of beta cell function; HOMA-IR, homeostasis model assessment of insulin resistance; HPC, Health Promotion Center; LASA, Longitudinal Aging Study Amsterdam; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable; NR, not reported; SBMS, Severance Bone Metabolism study; SBP, systolic blood pressure; SOF, Study of Osteoporotic Fractures; SOS, Shanghai Obesity Study; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHR, waist-to-hip ratio

SUPPLEMENTARY MATERIAL

Appendix 1	PRISMA checklist
Appendix 2	MOOSE checklist
Appendix 3	MEDLINE literature search strategy
Appendix 4	Modified Newcastle Ottawa Quality Scale for cross-sectional studies
Appendix 5	Reference list of included studies

Appendix 1. PRISMA checklist

Section/topic	Item No	Checklist item	Reported on page No
Title			
Title	1	Identify the report as a systematic review, meta-analysis, or both	1
Abstract			
Structured summary	2	Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review registration number	2
Introduction			
Rationale	3	Describe the rationale for the review in the context of what is already known	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS)	4
Methods			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information including registration number	4
Eligibility criteria	6	Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication status) used as criteria for eligibility, giving rationale	4
Information sources	7	Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated	Appendix 3
Study selection	9	State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)	4-5
Data collection process	10	Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators	5
Data items	11	List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made	5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis	5
Summary measures	13	State the principal summary measures (such as risk ratio, difference in means).	5-6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I^2 statistic) for each meta-analysis	5-6
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies)	6
Additional analyses	16	Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified	6
Results			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram	6 and Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations	6-7, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12).	7, Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot	7-10
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency	7-10, Figures 2-4
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see item 15)	7, Table 1
Additional analysis	23	Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16)	NA
Discussion			
Summary of evidence	24	Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as health care providers, users, and policy makers)	10-11
Limitations	25	Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, reporting bias)	12-13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research	13
Funding			
Funding	27	Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic review	None

Appendix 2. MOOSE checklist

Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis

Criteria		Brief description of how the criteria were handled in the review
Reporting of background		
√	Problem definition	The data on the associations of circulating osteocalcin (OC) with cardiovascular disease (CVD) are sparse and conflicting. In this context, we have carried out a comprehensive systematic meta-analysis to quantify the associations of circulating OC (total, undercarboxylated, and carboxylated with cardiovascular outcomes (clinical CVD endpoints and intermediate cardiovascular phenotypes).
√	Hypothesis statement	Circulating levels of OC are associated with cardiovascular outcomes
√	Description of study outcomes	CVD-related outcomes [composite CVD, coronary heart disease (CHD), stroke, congestive heart failure (CHF), or all-cause mortality]; and (ii) intermediate cardiovascular traits [carotid atherosclerosis, aortic atherosclerosis, coronary artery calcification (CAC), carotid intima-media thickness (CMT), abdominal aortic calcification (AAC)].
√	Type of exposure	Blood circulating levels of OC (total OC, undercarboxylated OC, and carboxylated OC
√	Type of study designs used	Observational cohort, case-control, or cross-sectional population-based studies
√	Study population	Healthy participants, pre- and post-menopausal women, as well as participants with pre-existing conditions such as metabolic syndrome, type 2 diabetes, and participants at high cardiovascular risk
Reporting of search strategy should include		
√	Qualifications of searchers	Samuel Seidu, MD; Setor Kunutsor, PhD
√	Search strategy, including time period included in the synthesis and keywords	Time period: from inception of MEDLINE and EMBASE to 22 March 2019. Search strategy: The detailed search strategy can be found in Appendix 3.
√	Databases and registries searched	MEDLINE and EMBASE
√	Search software used, name and version, including special features	OvidSP was used to search EMBASE EndNote used to manage references
√	Use of hand searching	We searched bibliographies of retrieved papers
√	List of citations located and those excluded, including justifications	Details of the literature search process are outlined in the flow chart. The citation list for excluded studies is available upon request.
√	Method of addressing articles published in languages other than English	We placed no restrictions on language
√	Method of handling abstracts and unpublished studies	Not applicable
√	Description of any contact with authors	We contacted authors who had conducted univariate or multivariate analysis with osteocalcin as an exposure and cardiovascular outcomes but had not reported relevant estimates.
Reporting of methods should include		
√	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	Detailed inclusion and exclusion criteria are described in the Methods section.
√	Rationale for the selection and	Data extracted from each of the studies were relevant to the

	coding of data	population characteristics, study design, exposure, outcome, and possible effect modifiers of the association.
√	Assessment of confounding	We assessed confounding by ranking individual studies on the basis of different adjustment levels.
√	Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results	Study quality was assessed based on the nine-star Newcastle–Ottawa Scale using pre-defined criteria namely: population representativeness, comparability (adjustment of confounders), ascertainment of outcome.
√	Assessment of heterogeneity	Limited data precluded assessment of heterogeneity
√	Description of statistical methods in sufficient detail to be replicated	Description of methods of meta-analyses and assessment of publication bias are detailed in the methods. We performed random effects meta-analysis with Stata 14.
√	Provision of appropriate tables and graphics	See Figures 2-4; Table 1
Reporting of results should include		
√	Graph summarizing individual study estimates and overall estimate	Figures 2-4
√	Table giving descriptive information for each study included	Table 1
√	Results of sensitivity testing	NA
√	Indication of statistical uncertainty of findings	95% confidence intervals were presented with all summary estimates
Reporting of discussion should include		
√	Quantitative assessment of bias	The systematic review is limited in scope, as it involves published data. Individual participant data is needed. Limitations have been discussed.
√	Justification for exclusion	All studies were excluded based on the pre-defined inclusion criteria in methods section.
√	Assessment of quality of included studies	Brief discussion included in 'Methods' section
Reporting of conclusions should include		
√	Consideration of alternative explanations for observed results	We discussed that potential unmeasured confounders may have caused residual confounding. Additionally, our findings could have been over-estimated somewhat due to preferential publication of extreme findings. The variations in the strengths of association may also be due to true population differences, or to differences in quality of studies.
√	Generalization of the conclusions	Discussed in the context of the results.
√	Guidelines for future research	We recommend large-scale prospective data
√	Disclosure of funding source	No separate funding was necessary for the undertaking of this systematic review.

Appendix 3. MEDLINE literature search strategy

- 1 exp OSTEOCALCIN/bi [Blood] (3992)
- 2 exp Cardiovascular Diseases/ (2257611)
- 3 exp Coronary Disease/ (209108)
- 4 exp Coronary Artery Disease/ (56488)
- 5 exp STROKE/ 120515 ()
- 6 exp ATHEROSCLEROSIS/ (38589)
- 7 exp Carotid Intima-Media Thickness/ (4196)
- 8 exp Vascular Calcification/ (3505)
- 9 aortic calcification.mp. (1019)
- 10 exp MORTALITY/ (356269)
- 11 exp Heart Failure/ (112241)
- 12 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (2536035)
- 13 1 and 12 (155)
- 14 limit 13 to (humans and "all adult (19 plus years)") (126)

Each part was specifically translated for searching alternative databases.

Appendix 4. Modified Newcastle Ottawa Quality Scale for cross-sectional studies

The methodological quality score is based on New-Castle Ottawa Quality Scale and is adapted for this review. Maximum of one star can be awarded for each item in Selection and Outcome categories. A maximum of two stars can be given for Comparability items.

Cut-off scores

Low methodological quality 0-3 stars

Moderate methodological quality 4-6 stars

High methodological quality 7-8 stars (>75%)

Category 1: Selection

1. Representativeness of the sample

- (a) Truly representative if the sample is randomly derived from the general population with sample size of >100 subjects *
- (b) Somewhat representative sample from the population with sample size of >100*
- (c) Selected group of users (e.g., nurses, volunteers)
- (d) No description of the derivation of the cases.

2. Non-respondents

- (a) Comparability between respondents and non-respondents characteristics is established, and the response rate is satisfactory*
- (b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory
- (c) No description of the response rate or the characteristics of the responders and the non-responders

3. Adequate definition of exposure

- (a) Yes, according to a clear and widely used definition *
- (b) Yes, from record linkage or based on self-reports
- (c) No description.

4. Ascertainment of exposure

- (a) Secure record*
- (b) Written self-report
- (c) No description

Category 2: Comparability

5. Comparability on the basis of the design/analysis

- (a) Study controls for age, sex, or BMI*
- (b) Study controls for any additional factor: Smoking status, education, alcohol intake, physical activity, lipids, or blood pressure)*

Category 3: Outcome

6. The study used a precise definition of outcome and valid and reliable method (individually for each relevant outcome)

7. Assessment of outcome

- (a) Independent blind assessment (reference to medical records)*
- (b) Record linkage (coded by ICD on database records)*
- (c) Self-report.
- (d) No description.

8. Statistical test

- (a) The statistical test used to analyse the data is clearly described and appropriate, and the measurement of the association is present, including confidence intervals and the probability level (p-value)*
- (b) The statistical test is not appropriate, not described or incomplete.

Appendix 5. Reference list of included studies

1. Jie KS, Bots ML, Vermeer C, Witteman JC, Grobbee DE. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. *Atherosclerosis*. 1995;116(1):117-123.
2. Schleithoff SS, Zittermann A, Stüttgen B, et al. Low serum levels of intact osteocalcin in patients with congestive heart failure. *Journal of bone and mineral metabolism*. 2003;21(4):247-252.
3. Montalcini T, Emanuele V, Ceravolo R, et al. Relation of low bone mineral density and carotid atherosclerosis in postmenopausal women. *Am J Cardiol*. 2004;94(2):266-269.
4. Pennisi P, Signorelli SS, Riccobene S, et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. *Osteoporos Int*. 2004;15(5):389-395.
5. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2009;94(1):45-49.
6. Okura T, Kurata M, Enomoto D, et al. Undercarboxylated osteocalcin is a biomarker of carotid calcification in patients with essential hypertension. *Kidney Blood Press Res*. 2010;33(1):66-71.
7. Parker BD, Bauer DC, Ensrud KE, Ix JH. Association of osteocalcin and abdominal aortic calcification in older women: the study of osteoporotic fractures. *Calcif Tissue Int*. 2010;86(3):185-191.
8. Zhang Y, Qi L, Gu W, et al. Relation of serum osteocalcin level to risk of coronary heart disease in Chinese adults. *Am J Cardiol*. 2010;106(10):1461-1465.
9. Bao Y, Zhou M, Lu Z, et al. Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men. *Clin Endocrinol (Oxf)*. 2011;75(2):196-201.
10. Golasch G, Blessberger H, Azar D, et al. Markers of bone metabolism in premature myocardial infarction (≤ 40 years of age). *Bone*. 2011;48(3):622-626.
11. Kanazawa I, Yamaguchi T, Sugimoto T. Relationship between bone biochemical markers versus glucose/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2011;92(3):393-399.
12. Kim KJ, Kim KM, Park KH, et al. Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin. *Calcif Tissue Int*. 2012;91(6):370-378.
13. Reyes-Garcia R, Rozas-Moreno P, Jimenez-Moleon JJ, et al. Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes. *Diabetes Metab*. 2012;38(1):76-81.
14. Yeap BB, Chubb SA, Flicker L, et al. Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study. *Osteoporos Int*. 2012;23(2):599-606.
15. Confavreux CB, Szulc P, Casey R, et al. Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort. *J Clin Endocrinol Metab*. 2013;98(3):1084-1092.
16. Lerchbaum E, Schwetz V, Pilz S, et al. Association of bone turnover markers with mortality in men referred to coronary angiography. *Osteoporosis International*. 2013;24(4):1321-1332.
17. Ogawa-Furuya N, Yamaguchi T, Yamamoto M, Kanazawa I, Sugimoto T. Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus. *Osteoporos Int*. 2013;24(8):2223-2230.
18. Sheng L, Cao W, Cha B, Chen Z, Wang F, Liu J. Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2013;12:22.

19. Yamashita T, Okano K, Tsuruta Y, Akiba T, Nitta K. Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients. *Int Urol Nephrol*. 2013;45(1):207-214.
20. Yang R, Ma X, Dou J, et al. Relationship between serum osteocalcin levels and carotid intima-media thickness in Chinese postmenopausal women. *Menopause*. 2013;20(11):1194-1199.
21. Holvik K, van Schoor NM, Eekhoff EM, et al. Plasma osteocalcin levels as a predictor of cardiovascular disease in older men and women: a population-based cohort study. *European journal of endocrinology / European Federation of Endocrine Societies*. 2014;171(2):161-170.
22. Lerchbaum E, Schwetz V, Pilz S, Boehm BO, Marz W. Association of bone turnover markers with mortality in women referred to coronary angiography: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. *Osteoporos Int*. 2014;25(2):455-465.
23. Ma H, Lin H, Hu Y, et al. Serum levels of osteocalcin in relation to glucose metabolism and carotid atherosclerosis in Chinese middle-aged and elderly male adults: the Shanghai Changfeng Study. *European journal of internal medicine*. 2014;25(3):259-264.
24. Hwang YC, Kang M, Cho IJ, et al. Association between the Circulating Total Osteocalcin Level and the Development of Cardiovascular Disease in Middle-aged Men: A Mean 8.7-year Longitudinal Follow-up Study. *J Atheroscler Thromb*. 2015;22(2):136-143.
25. Yeap BB, Alfonso H, Chubb SA, et al. Proportion of Undercarboxylated Osteocalcin and Serum P1NP Predict Incidence of Myocardial Infarction in Older Men. *J Clin Endocrinol Metab*. 2015;100(10):3934-3942.
26. Zhang M, Ni Z, Zhou W, Qian J. Undercarboxylated osteocalcin as a biomarker of subclinical atherosclerosis in non-dialysis patients with chronic kidney disease. *J Biomed Sci*. 2015;22:75.
27. Kim KM, Lim S, Moon JH, et al. Lower uncarboxylated osteocalcin and higher sclerostin levels are significantly associated with coronary artery disease. *Bone*. 2016;83:178-183.
28. Choi BH, Joo NS, Kim MJ, Kim KM, Park KC, Kim YS. Coronary artery calcification is associated with high serum concentration of undercarboxylated osteocalcin in asymptomatic Korean men. *Clin Endocrinol (Oxf)*. 2015;83(3):320-326.
29. Maser RE, Lenhard MJ, Sneider MB, Pohlig RT. Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes. *Endocr Pract*. 2015;21(1):14-22.
30. Deng H, Lu H, Dai Y, Li L, Cao J, Zhu D. Relationship between Serum Osteocalcin and Carotid Atherosclerosis in Middle-Aged Men in China: A Cross-Sectional Study. *Biomed Res Int*. 2018;2018:1751905.
31. Ling Y, Wang Z, Wu B, Gao X. Association of bone metabolism markers with coronary atherosclerosis and coronary artery disease in postmenopausal women. *Journal of bone and mineral metabolism*. 2018;36(3):352-363.
32. Zhang X, Shen Y, Xu Y, et al. Association of serum osteocalcin levels with major adverse cardiovascular events: A 4.4-year retrospective cohort study. *Clinical and experimental pharmacology & physiology*. 2018;45(1):3-9.